Article Figures & Data
Tables
Characteristic Frequency, n Proportion, % Mean age, years (±SD) 51.48 (±19.1) – Sex Male 183 46.1 Female 214 53.9 Indication for CBD prescription Non-cancer pain symptoms 181 45.6 Mental health symptoms 64 16.1 Neurological symptoms 60 15.1 Cancer symptoms 92 23.2 Indication for CBD prescription Domain of
EQ-5D-5LBaseline EQ-5D-5L scores, median (IQR) Follow-up EQ-5D-5L scores, median (IQR) P v alue Non-cancer pain symptoms (n = 53) Mobility 2.0 (1.0 to 3.0) 2.0 (1.0 to 3.0) 0.022 Self-care 1.0 (1.0 to 2.0) 1.0 (1.0 to 2.0) 0.046 Usual activities 3.0 (2.0 to 4.0) 2.0 (1.0 to 3.0) 0.007 Pain/discomfort 3.5 (3.0 to 4.0) 3.0 (2.0 to 3.0) <0.001 Anxiety/depression 2.0 (1.0 to 3.0) 2.0 (1.0 to 2.0) 0.017 Mental health symptoms (n = 21) Mobility 1.0 (1.0 to 1.0) 1.0 (1.0 to 1.0) 0.577 Self-care 1.0 (1.0 to 1.75) 1.0 (1.0 to 1.0) 0.096 Usual activities 3.0 (2.0 to 3.0) 1.0 (1.0 to 2.0) 0.002 Pain/discomfort 2.0 (1.0 to 3.0) 1.0 (1.0 to 2.0) 0.039 Anxiety/depression 4.0 (3.0 to 4.0) 2.0 (1.5 to 3.0) 0.002 Neurological symptoms (n = 11) Mobility 1.0 (1.0 to 3.0) 1.5 (1.0 to 2.0) 0.317 Self-care 1.0 (1.0 to 3.0) 1.5 (1.0 to 2.0) 0.317 Usual activities 3.0 (1.75 to 4.0) 2.5 (1.75 to 3.25) 0.194 Pain/discomfort 3.0 (1.5 to 3.5) 3.0 (1.5 to 3.0) 0.18 Anxiety/depression 3.0 (2.0 to 3.0) 1.5 (1.0 to 3.0) 0.194 Cancer symptoms (n = 24) Mobility 1.0 (1.0 to 2.0) 1.0 (1.0 to 2.0) 0.56 Self-care 1.0 (1.0 to 2.0) 1.0 (1.0 to 1.0) 1 Usual activities 2.0 (1.0 to 2.75) 2.0 (1.0 to 3.0) 1 Pain/discomfort 3.0 (2.0 to 3.0) 2.0 (1.0 to 2.5) 0.047 Anxiety/depression 2.0 (1.0 to 3.0) 1.0 (1.0 to 2.0) 0.11 Score of 1 = no problems, 2 = slight problems, 3= moderate problems, 4 = severe problems, 5 = extreme problems. P values are calculated from Wilcoxon rank sum tests. ‘Before’ scores taken at first consultation. ‘After’ scores taken after at least 3 weeks of cannabidiol intake.
CBD = cannabidiol. IQR = interquartile range.
Side effect Frequency, n (%) Positive effects Improved sleep 31 (12.3) Improved appetite 7 (2.8) Adverse effects Sedation 5 (2.0) Vivid dreams 5 (2.0) Emotional disturbances eg, irritable, depressed, anxious 5 (2.0) Disorientation 3 (1.2) Sleeplessness 1 (0.4) Nausea 1 (0.4) Constipation 1 (0.4) Diarrhoea 1 (0.4) Headaches 1 (0.4) Oral mucosa irritation 1 (0.4) Hallucinations 1 (0.4)
In this issue
Cannabidiol prescription in clinical practice: an audit on the first 400 patients in New Zealand
Jump to section
Keywords
More in this TOC Section
Related Articles
Cited By...
Intended for Healthcare Professionals
